Ask most people what cardiovascular risk factors they know, and they'll list cholesterol, blood pressure, smoking, diabetes, and family history. Very few will mention Lp(a). And yet this single inherited lipoprotein affects roughly 20% of the population and, when elevated, more than doubles the risk of heart attack and stroke — entirely independent of LDL cholesterol.
It is one of the most clinically significant cardiovascular risk factors that most patients have never had tested.
What Is Lp(a)?
Lipoprotein(a) — pronounced "L-P-little-a" — is a lipoprotein particle consisting of an LDL-like core bound to a unique protein called apolipoprotein(a). What makes Lp(a) especially important — and especially challenging — is that its blood levels are almost entirely genetically determined. Unlike LDL, which responds substantially to diet and medication, your Lp(a) level is largely set at birth. You can eat a perfect diet, exercise daily, and maintain ideal body weight, and if your genes dictate elevated Lp(a), it will remain elevated.
Lp(a) at a Glance
Why Is Lp(a) Dangerous?
Lp(a) promotes cardiovascular disease through three mechanisms simultaneously:
- Atherosclerosis promotion — Lp(a) particles deposit within arterial walls, contributing directly to plaque formation and growth at levels independent of LDL
- Thrombotic activity — the apolipoprotein(a) component has structural similarity to plasminogen, a clot-dissolving protein. Lp(a) competes with plasminogen and inhibits clot breakdown, increasing the risk of acute thrombotic events
- Inflammatory signaling — Lp(a) carries oxidized phospholipids that directly stimulate arterial wall inflammation, accelerating plaque vulnerability
Additionally, elevated Lp(a) is one of the strongest known risk factors for calcific aortic stenosis — a narrowing of the aortic valve that is increasingly common in older adults and carries significant morbidity. This makes knowing your Lp(a) relevant not just for coronary artery disease but for valvular heart disease as well.
Critically, Lp(a) exerts these effects even in individuals with otherwise excellent lipid profiles. This explains why some patients have heart attacks "without any risk factors" — their Lp(a) was silently driving risk the entire time.
Who Should Be Tested?
Major cardiology societies including the European Society of Cardiology now recommend Lp(a) testing at least once in every adult's lifetime. The American Heart Association supports its use in patients with intermediate or borderline risk where the treatment decision is uncertain. Testing is especially indicated if you have:
- Family history of premature heart disease (before age 55 in men, 65 in women)
- A personal history of cardiovascular events despite well-controlled LDL
- A first-degree relative known to have elevated Lp(a)
- Calcific aortic stenosis
- Intermediate ASCVD risk where the treatment decision is uncertain
📋 One Test, Lifelong Information
Unlike LDL, Lp(a) remains stable throughout adult life. A single measurement provides information that is clinically relevant for decades. It is a simple blood draw, and there is no reason not to know your number.
What Can Be Done About Elevated Lp(a)?
This is where the conversation becomes nuanced — and where expert guidance is especially valuable.
Aggressive LDL Reduction
While Lp(a) cannot currently be substantially lowered with available medications, the overall atherosclerotic burden is determined by the sum of atherogenic particles. Patients with elevated Lp(a) should target significantly lower LDL levels than the general population — often below 55 mg/dL — to compensate for the Lp(a)-mediated residual risk. This is why cardiologists who understand Lp(a) often treat these patients more aggressively from the start.
PCSK9 Inhibitors
The PCSK9 inhibitor class (evolocumab, alirocumab) modestly reduces Lp(a) — typically by 20–30% — in addition to their primary LDL-lowering effect. For patients with both elevated LDL and elevated Lp(a), these medications offer dual benefit.
Emerging RNA-Based Therapies
RNA-based therapies specifically targeting the Lp(a) gene are currently in Phase 3 clinical trials and have demonstrated up to 90% reductions in Lp(a) levels. This represents a potential paradigm shift for the 20% of the population with inherited elevation. These treatments are being watched closely by the cardiovascular community.
More Rigorous Everything Else
Knowing your Lp(a) is elevated motivates more rigorous attention to every other modifiable risk factor. Smoking cessation, optimal blood pressure control, metabolic optimization, anti-inflammatory lifestyle, and regular aerobic exercise all take on added urgency when Lp(a) is known to be high. More frequent cardiovascular monitoring — including coronary artery calcium scoring — is also often warranted.
The Bottom Line
If you have never had your Lp(a) measured, you are missing a significant piece of your cardiovascular risk picture. At ElinMed, Dr. Nyange includes Lp(a) testing in the comprehensive cardiovascular risk panel for patients seeking optimization — because you cannot manage a risk factor you don't know exists, and because informed patients make fundamentally different decisions about their health.
Ready to Optimize Your Heart Health?
Book a virtual consultation with Dr. Nyange — same-week appointments throughout New York State.
Book a Visit